Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma

You may not be if

• Willingness to sign an informed consent and undergo study tests
• Willingness to receive cytoreductive chemotherapy, if necessary to debulk tumors prior to T cell administration, and to receive cyclophosphamide for lymphodepletion
• Serologic evidence of prior exposure to Epstein-Barr virus (EBV)
• Meets safety criteria to undergo leukapheresis
• Hemoglobin \> 9.0 gm/dL
• White blood cell (WBC) \> 2500 per microliter
• Alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase \[SGPT\]) =\< 2.5 x Upper Limit of Normal
• Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\]) =\< 2.5 x Upper Limit of Normal
• Creatinine =\< 1.6 mg/dL
• Willingness to use acceptable (barrier or hormonal methods) birth control as appropriate during the course of the study
• Treatment with fludarabine or cladribine within the previous 2 years prior to apheresis
• Known central nervous system involvement with NHL
• Pulmonary involvement with NHL; a diagnosis of pulmonary lymphoma will be based in part on findings from chest computed tomography (CT) and, if clinically appropriate, lung biopsy
• Exposure to chemotherapeutic agents (standard or experimental) or other immunosuppressive therapies less than four weeks prior to apheresis; patients must have recovered from acute side effects of such therapy
• Positive serology for human immunodeficiency virus (HIV)
• Active Hepatitis B or Hepatitis C infection
• History of hypersensitivity reactions to murine proteins or seropositivity for human anti-mouse antibody (HAMA)
• Requirement for corticosteroid therapy during the study period unless used specifically for amelioration of toxicity induced by transferred cells
• Treatment with anti-CD20 antibodies (rituximab, tositumomab, ibritumomab) within 4 months prior to start of T cell infusions
• Patients with lymph nodes in excess of 5 cm in diameter at time of T cell infusion
• Patients with \> 5000 circulating CD20+ lymphocytes per mm\^3 at time of T cell infusion
• Previous allogeneic stem cell transplantation
• Life expectancy less than 90 days
• Pregnancy